[{"id":"aa0ea678-0fd7-41d5-9cac-558568133e0c","acronym":"EBVision","url":"https://clinicaltrials.gov/study/NCT04554914","created_at":"2021-01-18T21:46:31.475Z","updated_at":"2025-02-25T15:11:41.557Z","phase":"Phase 2","brief_title":"A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases","source_id_and_acronym":"NCT04554914 - EBVision","lead_sponsor":"Atara Biotherapeutics","biomarkers":" CD20","pipe":" | ","alterations":" CD20 negative","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tab-cel (tabelecleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 190","initiation":"Initiation: 07/14/2021","start_date":" 07/14/2021","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2025-02-13"},{"id":"8f439945-e5eb-40b9-a7e6-6eb64cdd7790","acronym":"","url":"https://clinicaltrials.gov/study/NCT01409161","created_at":"2021-01-18T05:47:46.957Z","updated_at":"2025-02-25T17:35:27.084Z","phase":"Phase 2","brief_title":"Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT01409161","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" RARA • PML","pipe":"","alterations":" ","tags":["RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • Vesanoid (tretinoin) • arsenic trioxide"],"overall_status":"Recruiting","enrollment":" Enrollment 151","initiation":"Initiation: 10/05/2011","start_date":" 10/05/2011","primary_txt":" Primary completion: 12/18/2025","primary_completion_date":" 12/18/2025","study_txt":" Completion: 12/18/2025","study_completion_date":" 12/18/2025","last_update_posted":"2025-01-28"},{"id":"6b26b0df-c972-4fed-adba-6edb4b098b89","acronym":"KEYNOTE-D88","url":"https://clinicaltrials.gov/study/NCT05572684","created_at":"2022-10-10T15:07:08.123Z","updated_at":"2025-02-25T16:18:14.094Z","phase":"Phase 1/2","brief_title":"A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors","source_id_and_acronym":"NCT05572684 - KEYNOTE-D88","lead_sponsor":"NextCure, Inc.","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • NC410"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 10/06/2022","start_date":" 10/06/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-12-16"},{"id":"dfbc062f-ed24-4f40-8bd7-edd7973cf532","acronym":"","url":"https://clinicaltrials.gov/study/NCT04919369","created_at":"2021-06-10T01:52:31.476Z","updated_at":"2024-07-02T16:35:14.922Z","phase":"Phase 1","brief_title":"All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04919369","lead_sponsor":"Dwight Owen","biomarkers":" PD-L1 • ALK","pipe":"","alterations":" ","tags":["PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Vesanoid (tretinoin)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 10/18/2021","start_date":" 10/18/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-13"},{"id":"2fb170a4-c1bb-478b-9a26-3efad1e342ff","acronym":"ARYA-2","url":"https://clinicaltrials.gov/study/NCT04634357","created_at":"2022-04-24T10:00:30.724Z","updated_at":"2024-07-02T16:35:15.791Z","phase":"Phase 1/2","brief_title":"ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma","source_id_and_acronym":"NCT04634357 - ARYA-2","lead_sponsor":"Eureka Therapeutics Inc.","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ET140203"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 07/19/2022","start_date":" 07/19/2022","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2028","study_completion_date":" 01/31/2028","last_update_posted":"2024-03-07"},{"id":"2c9d4247-97d3-4cff-bce6-48a72101574c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04282044","created_at":"2021-01-18T20:47:23.693Z","updated_at":"2024-07-02T16:35:20.161Z","phase":"Phase 1","brief_title":"Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies","source_id_and_acronym":"NCT04282044","lead_sponsor":"BioEclipse Therapeutics","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • CRX100"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/08/2021","start_date":" 01/08/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-02-08"},{"id":"2aab645e-82e6-4871-a584-636d0a665d5d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04897490","created_at":"2021-05-21T11:52:52.627Z","updated_at":"2024-07-02T16:35:24.138Z","phase":"","brief_title":"RWE of 1st Line Treatment With ATO/ATRA for Adult APL","source_id_and_acronym":"NCT04897490","lead_sponsor":"Grupo Argentino de Tratamiento de la Leucemia Aguda","biomarkers":" BCR","pipe":" | ","alterations":" FLT3 mutation","tags":["BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vesanoid (tretinoin) • arsenic trioxide"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 03/01/2021","start_date":" 03/01/2021","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-01-09"},{"id":"df5b5086-1697-4c00-8ecc-c22d551b5706","acronym":"","url":"https://clinicaltrials.gov/study/NCT02339740","created_at":"2021-01-18T11:07:04.205Z","updated_at":"2024-07-02T16:35:28.404Z","phase":"Phase 3","brief_title":"Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT02339740","lead_sponsor":"Children's Oncology Group","biomarkers":" FLT3 • RARA • PML","pipe":" | ","alterations":" FLT3 mutation • FLT3 wild-type","tags":["FLT3 • RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • mitoxantrone • Vesanoid (tretinoin) • arsenic trioxide • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 158","initiation":"Initiation: 07/21/2015","start_date":" 07/21/2015","primary_txt":" Primary completion: 10/31/2020","primary_completion_date":" 10/31/2020","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2023-11-22"},{"id":"f2db16c9-71f0-4157-a48e-228ddfc05996","acronym":"DECIST","url":"https://clinicaltrials.gov/study/NCT04157127","created_at":"2021-01-29T07:19:57.046Z","updated_at":"2024-07-02T16:35:28.793Z","phase":"Phase 1","brief_title":"Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT04157127 - DECIST","lead_sponsor":"Baylor College of Medicine","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dubodencel (DOC1021)"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 08/03/2020","start_date":" 08/03/2020","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2023-11-18"},{"id":"37ba8d01-7c78-43cc-81e1-59e78827f9d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04367675","created_at":"2021-01-18T21:06:34.302Z","updated_at":"2024-07-02T16:35:32.189Z","phase":"Phase 1b","brief_title":"INO 5401 Vaccination in BRCA1/2 Mutation Carriers","source_id_and_acronym":"NCT04367675","lead_sponsor":"University of Pennsylvania","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e INO-5401 • rocakinogene sifuplasmid (INO-9012)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 04/20/2021","start_date":" 04/20/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-10-23"},{"id":"3212545e-61a5-4679-863b-11a4f4ec1221","acronym":"ATRA","url":"https://clinicaltrials.gov/study/NCT04113863","created_at":"2021-01-18T20:06:42.396Z","updated_at":"2024-07-02T16:35:32.515Z","phase":"Phase 2","brief_title":"Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer","source_id_and_acronym":"NCT04113863 - ATRA","lead_sponsor":"Mario Negri Institute for Pharmacological Research","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anastrozole • Vesanoid (tretinoin)"],"overall_status":"Recruiting","enrollment":" Enrollment 112","initiation":"Initiation: 06/18/2019","start_date":" 06/18/2019","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-10-19"},{"id":"c80eeae2-933f-4349-b377-8932b9e3ffc9","acronym":"rQNestin","url":"https://clinicaltrials.gov/study/NCT03152318","created_at":"2022-10-22T19:05:45.181Z","updated_at":"2024-07-02T16:35:40.606Z","phase":"Phase 1","brief_title":"A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2","source_id_and_acronym":"NCT03152318 - rQNestin","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation • IDH1 R132H • IDH wild-type • IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH1 R132H • IDH wild-type • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • linoserpaturev (CAN-3110)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 07/18/2017","start_date":" 07/18/2017","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-08-08"},{"id":"499a3418-3780-4d53-819e-a9b110bd48a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03990493","created_at":"2021-01-18T19:37:12.031Z","updated_at":"2024-07-02T16:35:43.740Z","phase":"Phase 1","brief_title":"Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma","source_id_and_acronym":"NCT03990493","lead_sponsor":"PrimeVax Immuno-Oncology Inc.","biomarkers":" PD-L1 • BRAF","pipe":"","alterations":" ","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PV-001-DC • PV-001-DV"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-07-06"},{"id":"7c9b75c3-9f92-43f5-9d62-39a684b29dbf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03989895","created_at":"2021-01-18T19:37:02.966Z","updated_at":"2024-07-02T16:35:43.820Z","phase":"Phase 1","brief_title":"Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Melanoma","source_id_and_acronym":"NCT03989895","lead_sponsor":"PrimeVax Immuno-Oncology Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" BRAF mutation","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PV-001-DC • PV-001-DV"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-07-06"},{"id":"8b19687d-558a-4223-bbd4-26df46c73f8c","acronym":"DEMAND","url":"https://clinicaltrials.gov/study/NCT04741984","created_at":"2021-02-05T12:56:19.857Z","updated_at":"2024-07-02T16:35:47.995Z","phase":"Phase 1","brief_title":"Monocyte Antigen Carrier Cells for Newly Diagnosed GBM","source_id_and_acronym":"NCT04741984 - DEMAND","lead_sponsor":"Michael Gunn","biomarkers":" MGMT • IFNG • GZMB","pipe":"","alterations":" ","tags":["MGMT • IFNG • GZMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • MT-201 • adecatumumab (MT201)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2023-05-15"},{"id":"6193f02a-522d-4868-bdfe-0cbcfe1502ee","acronym":"SQZ-PBMC-HPV-101","url":"https://clinicaltrials.gov/study/NCT04084951","created_at":"2021-06-30T14:53:47.022Z","updated_at":"2024-07-02T16:35:50.584Z","phase":"Phase 1","brief_title":"Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04084951 - SQZ-PBMC-HPV-101","lead_sponsor":"SQZ Biotechnologies","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • SQZ-PBMC-HPV"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 01/28/2020","start_date":" 01/28/2020","primary_txt":" Primary completion: 02/09/2023","primary_completion_date":" 02/09/2023","study_txt":" Completion: 02/09/2023","study_completion_date":" 02/09/2023","last_update_posted":"2023-04-14"},{"id":"8da9df0c-215f-464f-b7e6-4299e8415fe2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02759588","created_at":"2021-01-18T13:31:56.704Z","updated_at":"2024-07-02T16:35:58.169Z","phase":"Phase 1b","brief_title":"GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer","source_id_and_acronym":"NCT02759588","lead_sponsor":"Genelux Corporation","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • olvimulogene nanivacirepvec (GL-ONC1)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2023-01-05"},{"id":"d0527478-cd05-4416-b5a5-992a14d14ac7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03385486","created_at":"2021-05-11T12:52:51.133Z","updated_at":"2024-07-02T16:36:11.051Z","phase":"Phase 1","brief_title":"Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors","source_id_and_acronym":"NCT03385486","lead_sponsor":"Taiga Biotechnologies, Inc.","biomarkers":" CD69","pipe":"","alterations":" ","tags":["CD69"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TBX-3400"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 06/02/2019","start_date":" 06/02/2019","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-05-03"},{"id":"22ada351-a09a-47fd-823b-9e72ade6fd98","acronym":"","url":"https://clinicaltrials.gov/study/NCT04609215","created_at":"2021-01-19T20:32:05.021Z","updated_at":"2024-07-02T16:36:11.787Z","phase":"Phase 1/2","brief_title":"ImmunoBreast - A Phase Ib Study","source_id_and_acronym":"NCT04609215","lead_sponsor":"Henrik Ditzel","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 positive • HR positive • ER expression","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • ER expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • Alecsat (cytotoxic lymphocyte-based cancer vaccine)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/21/2020","start_date":" 04/21/2020","primary_txt":" Primary completion: 05/21/2023","primary_completion_date":" 05/21/2023","study_txt":" Completion: 05/21/2023","study_completion_date":" 05/21/2023","last_update_posted":"2022-04-20"},{"id":"91376b42-a448-49fc-b024-9ff401ca6c3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04640246","created_at":"2021-05-11T12:53:09.487Z","updated_at":"2024-07-02T16:36:17.708Z","phase":"Phase 1/2","brief_title":"Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies","source_id_and_acronym":"NCT04640246","lead_sponsor":"Taiga Biotechnologies, Inc.","biomarkers":" CD69","pipe":"","alterations":" ","tags":["CD69"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TBX-3400"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/25/2021","start_date":" 01/25/2021","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 04/01/2023","study_completion_date":" 04/01/2023","last_update_posted":"2022-02-02"},{"id":"0444b2f1-748a-4185-94b9-0f9f411e1ec7","acronym":"","url":"https://clinicaltrials.gov/study/NCT01149343","created_at":"2021-01-18T04:34:31.399Z","updated_at":"2024-07-02T16:36:38.411Z","phase":"Phase 1","brief_title":"Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer","source_id_and_acronym":"NCT01149343","lead_sponsor":"GlaxoSmithKline","biomarkers":" PRAME","pipe":" | ","alterations":" PRAME expression","tags":["PRAME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PRAME expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GSK2302025A • GSK2302032A"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 07/02/2010","start_date":" 07/02/2010","primary_txt":" Primary completion: 02/11/2014","primary_completion_date":" 02/11/2014","study_txt":" Completion: 12/19/2016","study_completion_date":" 12/19/2016","last_update_posted":"2020-11-20"},{"id":"e5587414-ede2-4832-a20e-9bd4ff957340","acronym":"","url":"https://clinicaltrials.gov/study/NCT03031249","created_at":"2021-01-18T14:55:11.899Z","updated_at":"2024-07-02T16:36:47.929Z","phase":"Phase 1/2","brief_title":"Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia","source_id_and_acronym":"NCT03031249","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital","biomarkers":" NPM1","pipe":" | ","alterations":" NPM1 mutation","tags":["NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Vesanoid (tretinoin) • arsenic trioxide"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 02/08/2017","start_date":" 02/08/2017","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2020-03-20"},{"id":"24ecc665-dd64-4425-8972-8b5aa267e94d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01051063","created_at":"2021-01-18T04:07:55.854Z","updated_at":"2024-07-02T16:37:05.020Z","phase":"Phase 1","brief_title":"Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy","source_id_and_acronym":"NCT01051063","lead_sponsor":"GlaxoSmithKline","biomarkers":" WT1","pipe":"","alterations":" ","tags":["WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GSK2130579A"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 12/09/2009","start_date":" 12/09/2009","primary_txt":" Primary completion: 04/26/2016","primary_completion_date":" 04/26/2016","study_txt":" Completion: 04/26/2016","study_completion_date":" 04/26/2016","last_update_posted":"2018-11-29"},{"id":"5a9cc975-6902-4148-8104-c6db0e87177c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00725283","created_at":"2021-02-01T11:52:15.287Z","updated_at":"2024-07-02T16:37:08.186Z","phase":"Phase 1","brief_title":"Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT00725283","lead_sponsor":"GlaxoSmithKline","biomarkers":" WT1","pipe":"","alterations":" ","tags":["WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GSK2130579A"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 10/01/2008","start_date":" 10/01/2008","primary_txt":" Primary completion: 06/22/2016","primary_completion_date":" 06/22/2016","study_txt":" Completion: 06/22/2016","study_completion_date":" 06/22/2016","last_update_posted":"2018-08-07"}]